Stay updated with breaking news from Eric Benevich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,150 shares of the company’s stock, valued at approximately $415,000. A number of other hedge funds also recently modified their […]
Yousif Capital Management LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,808 shares of the company’s stock after selling 370 shares during the quarter. Yousif Capital Management LLC’s […]
New York State Common Retirement Fund lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.1% during the 4th quarter, Holdings Channel reports. The firm owned 214,396 shares of the company’s stock after selling 29,456 shares during the quarter. New York State Common Retirement Fund’s holdings in Neurocrine Biosciences were worth $28,249,000 […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average […]
Wedbush reissued their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $147.00 target price on the stock. A number of other analysts also recently weighed in on NBIX. JPMorgan Chase & Co. increased their price target on shares […]